White blood cells >= /uL, within  weeks of randomization
White blood cells (WBC) >= , cells/uL (. x ^ L) or
Obtained within  days prior to course  day  (CD): White blood cells (WBC) >= /uL
White blood cells (WBC) >= /uL
White blood cells (WBC) >= ,/uL
Within  days of the first dose of study drug: White blood cells (WBCs) >= /uL
White blood cell (WBC) >= , cells/uL
Leukocytes (white blood cells [WBCs]) >= ,/uL.
White blood cells (WBCs) >= /microL within  days of study registration.
STUDY TREATMENT: White blood cells (WBC) >= /ul
White blood cells (WBC) >= ,/uL
White blood cells (WBC) >= /uL within  days prior to first dose
White blood cells (WBC) >= /uL
White blood cells >= /uL obtained <  weeks prior to starting treatment
Obtained within  days of randomization: White blood cells (WBCs) >= /uL
White blood cells (WBC)\t>= ,/uL
White blood cell (WBC) >=  cells/uL (obtained within  days prior to first study treatment)
White blood cells (WBC) >= /uL
White blood cells (WBC) >=  /uL
White blood cells (WBC) =< ,/uL
White blood cells (WBC) >= ,/uL
White blood cells (WBC) >= /uL
White blood cells (WBC) is >= /ul
White blood cells (WBC) >= /uL
White blood cells (WBC) >= ,/uL
Patients must have lymphocytosis with white blood cells between ,-,/uL in order to collect adequate leukemia cells for vaccine production
White blood cell (WBC) >= , cells/uL
White blood cells (WBC) >= ,/ul
White blood cells (WBC) >= ,/ul
White blood cells (WBC) >=  x ^/ul
White blood cells (WBC) >= /ul performed within  days of enrollment
Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least /uL
White blood cells (WBC) >= /uL
White blood cells /ul or more
White blood cells (WBC) >= /uL
White blood cells (WBC) >= /uL
White blood cell (WBC) >= , cells/uL
White blood cells (WBC) >= /uL
White blood cell (WBC) >= , cells/uL
White blood cells (WBCs) >=  cells/uL
White blood cells (WBCs) >=  cells u/L
White blood cells (WBCs) >= /uL
White blood cells (WBCs) >= /uL
Prior to cyclophosphamide and T cell infusions: white blood cells (WBC) =< /uL
Within  days prior to registration: white blood cells (WBC) >= ,/uL
White blood cells (WBC) > /uL
Within  days prior to the first study treatment (cycle , day ): White blood cells (WBC) counts > /uL
White blood cells (WBCs) >= /uL
White blood cells (WBC) > /ul
White blood cells (WBC) < ,/ul
White blood cells (WBC) >=  cells/ul
White blood cell (WBC) >= , cells/uL
White blood cells (WBC) >= /uL
White blood cells (WBC) >= /uL
White blood cells (WBC) >= /ul
White blood cells (WBC) =< /uL
COHORT A: White blood cells (WBC) >= /uL
White blood cells (WBC) >= /uL
White blood cells (WBC)\t>= /uL
Obtained within  days prior to registration: White blood cells (WBC) >= ,/ul
White blood cells (WBC) >= /uL
White blood cells (WBC): >= /uL (~  x ^/L)
White blood cells (WBC) >= ,/ul
White blood cells (WBC) > . K/uL
Within  days prior to enrollment/randomization: White blood cells (WBC) >= . K/uL
White blood cells (WBC) >= . x ^/uL
White blood cells (WBC) >= . x ^/uL
White blood cells (WBC) < ,/ul at screening
White blood cells greater than . x ^/ul (or , cells/mm^); these results can be within last  days from the day of signing informed consent
White blood cells (WBC) >= ,/ul
White blood cells (WBC) >= /uL
White blood cells (WBC) >= ,/uL
Severe leukocytosis (white blood cell count [WBC] >= , cells /uL)
White blood cells (WBCs) >= /uL, obtained within  days of the first dose of study drug
White blood cells (WBCs) < . K/UL in the past  days
White blood cells (WBCs) < . K/UL in the past  days
Leukocytes (white blood cells [WBC]) >= ,/uL (>= ,/uL for African-American participants)
White blood cells (WBC) >  cells/uL
Within  days of eligibility confirmation: Leukocytes (white blood cells [WBC]) >= ,/uL
Obtained within  days prior to registration: White blood cell (WBC) >=  cells/uL
White blood cells >= ,/uL
White blood cells (WBC) > . X ^/uL